Katarzyna Kozlowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katarzyna Kozlowska has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Maria Siemionow
Department of Orthopaedics , University of Illinois at Chicago , Chicago , IL , USA
6 shared publications - Sonia Brodowska
Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA
6 shared publications - Kristina Zalants
Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA
3 shared publications - Paulina Langa
Advanced Cellular Therapeutics Facility (ACTF), University of Chicago Medical Center, Chicago, Illinois, USA
3 shared publications Ahlke Heydemann
Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, USA
2 shared publicationsKatarzyna Budzynska
Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA
2 shared publications
Latest Publications
- Open Access
- 3 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1633
Application of Human Epineural Patch (hEP) as a Novel Strategy for Nerve Protection and Enhancement of Regeneration After Nerve Crush Injury
Background: Numerous experimental studies aim to improve outcomes of peripheral nerve repair following trauma. This study evaluates the efficacy of the human epineural patch (hEP) compared to the human amniotic membrane (hAM) in promoting nerve regeneration following sciatic nerve crush injury. Methods: Thirty-six athymic nude rats were divided into three groups (n = 12 per group) following nerve crush: (1) an unprotected injury site; (2) crush injury wrapped with hEP; and (3) crush injury wrapped with hAM. Animals were assessed over 6 or 12 weeks post-injury. Evaluations included motor recovery (Toe-Spread test), sensory recovery (Pinprick test), muscle denervation atrophy (the gastrocnemius muscle index (GMI)), histomorphometry (myelin thickness, axonal density, fiber diameter, and percentage of myelinated fibers), and immunofluorescence (GFAP, Laminin B, NGF, S-100, VEGF, vWF, HLA-DR, and HLA-I) assessments. Results: The hEP group showed superior motor recovery, axonal density and higher GMI values compared to the hAM and control groups. The increased expression of neurogenic and angiogenic markers highlighted its neuroregenerative potential. Negligible HLA-DR and HLA-I expression confirmed the lack of hEP and hAM immunogenicity. Conclusions: The application of hEP following sciatic nerve crush injury facilitated nerve regeneration, improved functional outcomes, and offered a viable alternative to hAM. Structural stability and the regenerative capacity position hEP as a new, promising off-the-shelf product for nerve regeneration.
- 3 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1633
Open AccessApplication of Human Epineural Patch (hEP) as a Novel Strategy for Nerve Protection and Enhancement of Regeneration After Nerve Crush Injury
Background: Numerous experimental studies aim to improve outcomes of peripheral nerve repair following trauma. This study evaluates the efficacy of the human epineural patch (hEP) compared to the human amniotic membrane (hAM) in promoting nerve regeneration following sciatic nerve crush injury. Methods: Thirty-six athymic nude rats were divided into three groups (n = 12 per group) following nerve crush: (1) an unprotected injury site; (2) crush injury wrapped with hEP; and (3) crush injury wrapped with hAM. Animals were assessed over 6 or 12 weeks post-injury. Evaluations included motor recovery (Toe-Spread test), sensory recovery (Pinprick test), muscle denervation atrophy (the gastrocnemius muscle index (GMI)), histomorphometry (myelin thickness, axonal density, fiber diameter, and percentage of myelinated fibers), and immunofluorescence (GFAP, Laminin B, NGF, S-100, VEGF, vWF, HLA-DR, and HLA-I) assessments. Results: The hEP group showed superior motor recovery, axonal density and higher GMI values compared to the hAM and control groups. The increased expression of neurogenic and angiogenic markers highlighted its neuroregenerative potential. Negligible HLA-DR and HLA-I expression confirmed the lack of hEP and hAM immunogenicity. Conclusions: The application of hEP following sciatic nerve crush injury facilitated nerve regeneration, improved functional outcomes, and offered a viable alternative to hAM. Structural stability and the regenerative capacity position hEP as a new, promising off-the-shelf product for nerve regeneration.
- Open Access
- 1 January 2025
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 73 (1)
Protective Effect of the Human Epineural Patch Application after Sciatic Nerve Crush Injury Followed by Nerve Transection and End-to-End Repair
Nerve regeneration under unfavorable wound conditions remains challenging. We introduce the human epineural patch (hEP) as a novel nerve protector for post-trauma applications, comparing its regenerative efficacy with that of the human amniotic membrane (hAM). Following crush injury, transection, and end-to-end repair (CTR), 36 athymic nude rats were randomly assigned to six experimental groups ( n = 6 each): control (no-protection), hEP, or hAM application post-repair. Assessments at 6 weeks and 12 weeks included functional evaluation (Toe-Spread and Pinprick tests), gastrocnemius muscle index (GMI), histomorphometric analysis (myelin thickness, axonal density, fiber diameter, percentage of myelinated fibers), and immunofluorescence staining for neurogenic, angiogenic, and immunogenic markers. The hEP group exhibited superior motor (3.167 ± 0.167) and sensory (3.500 ± 0.212) recovery and GMI values (0.955 ± 0.014), compared with the No protection group ( p < 0.05). Myelin thickness (3.480 ± 0.019 µm, p < 0.0001), fiber diameter (10.788 ± 0.197 µm, p < 0.05), and myelinated fiber percentage (89.841% ± 0.453%, p < 0.01) were significantly higher in the hEP group. At 12 weeks, hEP application significantly increased the expression of Laminin B (2.083 ± 0.083), nerve growth factor (NGF) (1.750 ± 0.250), and vascular endothelial growth factor (VEGF) (2.667 ± 0.333), corresponding with improved function. The application of hEP at the sciatic nerve repair site after CTR injury significantly enhanced nerve regeneration compared with hAM. This study introduces hEP as a promising alternative nerve protector for traumatic nerve injuries.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 73 (1)
Open AccessProtective Effect of the Human Epineural Patch Application after Sciatic Nerve Crush Injury Followed by Nerve Transection and End-to-End Repair
Nerve regeneration under unfavorable wound conditions remains challenging. We introduce the human epineural patch (hEP) as a novel nerve protector for post-trauma applications, comparing its regenerative efficacy with that of the human amniotic membrane (hAM). Following crush injury, transection, and end-to-end repair (CTR), 36 athymic nude rats were randomly assigned to six experimental groups ( n = 6 each): control (no-protection), hEP, or hAM application post-repair. Assessments at 6 weeks and 12 weeks included functional evaluation (Toe-Spread and Pinprick tests), gastrocnemius muscle index (GMI), histomorphometric analysis (myelin thickness, axonal density, fiber diameter, percentage of myelinated fibers), and immunofluorescence staining for neurogenic, angiogenic, and immunogenic markers. The hEP group exhibited superior motor (3.167 ± 0.167) and sensory (3.500 ± 0.212) recovery and GMI values (0.955 ± 0.014), compared with the No protection group ( p < 0.05). Myelin thickness (3.480 ± 0.019 µm, p < 0.0001), fiber diameter (10.788 ± 0.197 µm, p < 0.05), and myelinated fiber percentage (89.841% ± 0.453%, p < 0.01) were significantly higher in the hEP group. At 12 weeks, hEP application significantly increased the expression of Laminin B (2.083 ± 0.083), nerve growth factor (NGF) (1.750 ± 0.250), and vascular endothelial growth factor (VEGF) (2.667 ± 0.333), corresponding with improved function. The application of hEP at the sciatic nerve repair site after CTR injury significantly enhanced nerve regeneration compared with hAM. This study introduces hEP as a promising alternative nerve protector for traumatic nerve injuries.
- 20 November 2023
- Published by Exemplum Tomasz Adamski in Chirurgia Narządów Ruchu i Ortopedia Polska
- Vol. 88 (4) , 178-182
Hook nail deformity in a child – treatment option with bone graft and thenar flap. Case study with pros and cons
- 20 November 2023
- Published by Exemplum Tomasz Adamski in Chirurgia Narządów Ruchu i Ortopedia Polska
- Vol. 88 (4) , 178-182
Hook nail deformity in a child – treatment option with bone graft and thenar flap. Case study with pros and cons
- Open Access
- 28 November 2022
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 19 (2) , 582-583
Correction: Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
- 28 November 2022
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 19 (2) , 582-583
Open AccessCorrection: Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
- 15 November 2022
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 39 (05) , 392-404
Assessment of Human Epineural Conduit of Different Size Diameters on Efficacy of Nerve Regeneration and Functional Outcomes
Background Different types of nerve conduits are used to bridge peripheral nerve gaps when a tension-free repair is unattainable. To best support nerve regeneration, naturally occurring conduits have been tested. Since allografts offer an unlimited source of epineurium, we have developed human epineural conduit (hEC) as a novel technology to bridge nerve gaps. Considering acellular properties, and lack of immunogenic response, epineurium-derived conduits represent an attractive material, when compared with nerve allografts that require systemic immunosuppression. In this study, we introduce the hEC as a novel naturally occurring material applied for repair of nerve gaps after trauma. Methods We tested the application of hEC created from human sciatic nerve in the restoration of 20 mm sciatic nerve defects in the nude rat model. Four experimental groups were studied: group 1: no repair control (n = 6), group 2: autograft control (n = 6), group 3: matched diameter hEC (n = 6), and group 4: large diameter hEC (n = 6). Functional tests of toe-spread and pin prick were performed at 1, 3, 6, 9, 12 weeks after repair. At 12 weeks, nerve samples were collected for immunostaining of Laminin B, S-100, glial fibrillary acidic protein (GFAP), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), von Willebrand factor, and histomorphometric analysis of myelin thickness, axonal density, fiber diameter, and percentage of the myelinated nerve fibers. Muscle samples were gathered for gastrocnemius muscle index (GMI) and muscle fiber area ratio measurements. Results Best functional recovery, as well as GMI, was revealed for the autograft group, and was comparable to the matched hEC group. Significant differences were revealed between matched and large hEC groups in expression of S100 (p = 0.0423), NGF (p = 0.269), VEGF (p = 0.0003) as well as in percentage of myelinated fibers (p < 0.001) and axonal density (p = 0.0003). Conclusion We established the feasibility of hEC creation. The innovative method introduces an alternative technique to autograft repair of nerve defects.
- 15 November 2022
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 39 (05) , 392-404
Assessment of Human Epineural Conduit of Different Size Diameters on Efficacy of Nerve Regeneration and Functional Outcomes
Background Different types of nerve conduits are used to bridge peripheral nerve gaps when a tension-free repair is unattainable. To best support nerve regeneration, naturally occurring conduits have been tested. Since allografts offer an unlimited source of epineurium, we have developed human epineural conduit (hEC) as a novel technology to bridge nerve gaps. Considering acellular properties, and lack of immunogenic response, epineurium-derived conduits represent an attractive material, when compared with nerve allografts that require systemic immunosuppression. In this study, we introduce the hEC as a novel naturally occurring material applied for repair of nerve gaps after trauma. Methods We tested the application of hEC created from human sciatic nerve in the restoration of 20 mm sciatic nerve defects in the nude rat model. Four experimental groups were studied: group 1: no repair control (n = 6), group 2: autograft control (n = 6), group 3: matched diameter hEC (n = 6), and group 4: large diameter hEC (n = 6). Functional tests of toe-spread and pin prick were performed at 1, 3, 6, 9, 12 weeks after repair. At 12 weeks, nerve samples were collected for immunostaining of Laminin B, S-100, glial fibrillary acidic protein (GFAP), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), von Willebrand factor, and histomorphometric analysis of myelin thickness, axonal density, fiber diameter, and percentage of the myelinated nerve fibers. Muscle samples were gathered for gastrocnemius muscle index (GMI) and muscle fiber area ratio measurements. Results Best functional recovery, as well as GMI, was revealed for the autograft group, and was comparable to the matched hEC group. Significant differences were revealed between matched and large hEC groups in expression of S100 (p = 0.0423), NGF (p = 0.269), VEGF (p = 0.0003) as well as in percentage of myelinated fibers (p < 0.001) and axonal density (p = 0.0003). Conclusion We established the feasibility of hEC creation. The innovative method introduces an alternative technique to autograft repair of nerve defects.
- Open Access
- 17 August 2022
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 70 (1) , 1-15
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
Duchenne muscular dystrophy (DMD) is a lethal disease caused by X-linked mutations in the dystrophin gene. Dystrophin deficiency results in progressive degeneration of cardiac, respiratory and skeletal muscles leading to premature death due to cardiopulmonary complications. Currently, no cure exists for DMD. Based on our previous reports confirming a protective effect of human dystrophin expressing chimeric (DEC) cell therapy on cardiac, respiratory, and skeletal muscle function after intraosseous administration, now we assessed long-term safety and biodistribution of human DEC therapy for potential clinical applications in DMD patients. Safety of different DEC doses (1 × 106 and 5 × 106) was assessed at 180 days after systemic-intraosseous administration to mdx/scid mice, a model of DMD. Assessments included: single cell gel electrophoresis assay (COMET assay) to confirm lack of genetic toxicology, magnetic resonance imaging (MRI) for tumorigenicity, and body, muscle and organ weights. Human DEC biodistribution to the target (heart, diaphragm, gastrocnemius muscle) and non-target (blood, bone marrow, lung, liver, spleen) organs was detected by flow cytometry assessment of HLA-ABC markers. Human origin of dystrophin was verified by co-localization of dystrophin and human spectrin by immunofluorescence. No complications were observed after intraosseous transplant of human DEC. COMET assay of donors and fused DEC cells confirmed lack of DNA damage. Biodistribution analysis of HLA-ABC expression revealed dose-dependent presence of human DEC cells in target organs, whereas negligible presence was detected in non-target organs. Human origin of dystrophin in the heart, diaphragm and gastrocnemius muscle was confirmed by co-localization of dystrophin expression with human spectrin. MRI revealed no evidence of tumor formation. Body mass and muscle and organ weights were stable and comparable to vehicle controls, further confirming DEC safety at 180 days post- transplant. This preclinical study confirmed long-term local and systemic safety of human DEC therapy at 180 days after intraosseous administration. Thus, DEC can be considered as a novel myoblast based advanced therapy medicinal product for DMD patients.
- 17 August 2022
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 70 (1) , 1-15
Open AccessLong-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
Duchenne muscular dystrophy (DMD) is a lethal disease caused by X-linked mutations in the dystrophin gene. Dystrophin deficiency results in progressive degeneration of cardiac, respiratory and skeletal muscles leading to premature death due to cardiopulmonary complications. Currently, no cure exists for DMD. Based on our previous reports confirming a protective effect of human dystrophin expressing chimeric (DEC) cell therapy on cardiac, respiratory, and skeletal muscle function after intraosseous administration, now we assessed long-term safety and biodistribution of human DEC therapy for potential clinical applications in DMD patients. Safety of different DEC doses (1 × 106 and 5 × 106) was assessed at 180 days after systemic-intraosseous administration to mdx/scid mice, a model of DMD. Assessments included: single cell gel electrophoresis assay (COMET assay) to confirm lack of genetic toxicology, magnetic resonance imaging (MRI) for tumorigenicity, and body, muscle and organ weights. Human DEC biodistribution to the target (heart, diaphragm, gastrocnemius muscle) and non-target (blood, bone marrow, lung, liver, spleen) organs was detected by flow cytometry assessment of HLA-ABC markers. Human origin of dystrophin was verified by co-localization of dystrophin and human spectrin by immunofluorescence. No complications were observed after intraosseous transplant of human DEC. COMET assay of donors and fused DEC cells confirmed lack of DNA damage. Biodistribution analysis of HLA-ABC expression revealed dose-dependent presence of human DEC cells in target organs, whereas negligible presence was detected in non-target organs. Human origin of dystrophin in the heart, diaphragm and gastrocnemius muscle was confirmed by co-localization of dystrophin expression with human spectrin. MRI revealed no evidence of tumor formation. Body mass and muscle and organ weights were stable and comparable to vehicle controls, further confirming DEC safety at 180 days post- transplant. This preclinical study confirmed long-term local and systemic safety of human DEC therapy at 180 days after intraosseous administration. Thus, DEC can be considered as a novel myoblast based advanced therapy medicinal product for DMD patients.
- Open Access
- 19 May 2022
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 18 (8) , 2872-2892
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a lethal disease caused by mutations in dystrophin encoding gene, causing progressive degeneration of cardiac, respiratory, and skeletal muscles leading to premature death due to cardiac and respiratory failure. Currently, there is no cure for DMD. Therefore, novel therapeutic approaches are needed for DMD patients.We have previously reported functional improvements which correlated with increased dystrophin expression following administration of dystrophin expressing chimeric (DEC) cells of myoblast origin to the mdx mouse models of DMD.In the current study, we confirmed dose-dependent protective effect of human DEC therapy created from myoblasts of normal and DMD-affected donors, on restoration of dystrophin expression and amelioration of cardiac, respiratory, and skeletal muscle function at 180 days after systemic-intraosseous DEC administration to mdx/scid mouse model of DMD. Functional improvements included maintenance of ejection fraction and fractional shortening levels on echocardiography, reduced enhanced pause and expiration time on plethysmography and improved grip strength and maximum stretch induced contraction of skeletal muscles. Improved function was associated with amelioration of mdx muscle pathology revealed by reduced muscle fibrosis, reduced inflammation and improved muscle morphology confirmed by reduced number of centrally nucleated fibers and normalization of muscle fiber diameters. Our findings confirm the long-term systemic effect of DEC therapy in the most severely affected by DMD organs including heart, diaphragm, and long skeletal muscles.These encouraging preclinical data introduces human DEC as a novel therapeutic modality of Advanced Therapy Medicinal Product (ATMP) with the potential to improve or halt the progression of DMD and enhance quality of life of DMD patients. Graphical Abstract Human DEC as a novel therapeutic modality with the potential to improve or halt progression of the DMD disease and enhance quality of life of DMD patients. Graphical abstract represents manufacturing process of the human DEC therapy for the future clinical applications. 1. We report the long-term efficacy of human DEC therapy resulting in increased dystrophin expression and reduced mdx muscle pathology after systemic-intraosseous administration of human Dystrophin Expressing Chimeric (DEC) Cells to the mdx/scid mouse model of DMD. 2. Systemic administration of human DEC therapy resulted in amelioration of cardiac, respiratory and skeletal muscle function as confirmed by echocardiography, plethysmography and standard muscle strength tests respectively. 3. We introduce human DEC as a novel Advanced Therapy Medicinal Product (ATMP) for future clinical application in DMD patients.
- 19 May 2022
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 18 (8) , 2872-2892
Open AccessLong-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a lethal disease caused by mutations in dystrophin encoding gene, causing progressive degeneration of cardiac, respiratory, and skeletal muscles leading to premature death due to cardiac and respiratory failure. Currently, there is no cure for DMD. Therefore, novel therapeutic approaches are needed for DMD patients.We have previously reported functional improvements which correlated with increased dystrophin expression following administration of dystrophin expressing chimeric (DEC) cells of myoblast origin to the mdx mouse models of DMD.In the current study, we confirmed dose-dependent protective effect of human DEC therapy created from myoblasts of normal and DMD-affected donors, on restoration of dystrophin expression and amelioration of cardiac, respiratory, and skeletal muscle function at 180 days after systemic-intraosseous DEC administration to mdx/scid mouse model of DMD. Functional improvements included maintenance of ejection fraction and fractional shortening levels on echocardiography, reduced enhanced pause and expiration time on plethysmography and improved grip strength and maximum stretch induced contraction of skeletal muscles. Improved function was associated with amelioration of mdx muscle pathology revealed by reduced muscle fibrosis, reduced inflammation and improved muscle morphology confirmed by reduced number of centrally nucleated fibers and normalization of muscle fiber diameters. Our findings confirm the long-term systemic effect of DEC therapy in the most severely affected by DMD organs including heart, diaphragm, and long skeletal muscles.These encouraging preclinical data introduces human DEC as a novel therapeutic modality of Advanced Therapy Medicinal Product (ATMP) with the potential to improve or halt the progression of DMD and enhance quality of life of DMD patients. Graphical Abstract Human DEC as a novel therapeutic modality with the potential to improve or halt progression of the DMD disease and enhance quality of life of DMD patients. Graphical abstract represents manufacturing process of the human DEC therapy for the future clinical applications. 1. We report the long-term efficacy of human DEC therapy resulting in increased dystrophin expression and reduced mdx muscle pathology after systemic-intraosseous administration of human Dystrophin Expressing Chimeric (DEC) Cells to the mdx/scid mouse model of DMD. 2. Systemic administration of human DEC therapy resulted in amelioration of cardiac, respiratory and skeletal muscle function as confirmed by echocardiography, plethysmography and standard muscle strength tests respectively. 3. We introduce human DEC as a novel Advanced Therapy Medicinal Product (ATMP) for future clinical application in DMD patients.
- 1 December 2019
- Published by Poznan University of Medical Sciences in Acta Medicorum Polonorum
- Vol. 9 (1-2) , 137-158
Poznan Clinic of Hand Surgery in the centenary of the Faculty of Medicine of the Poznan University
Artykuł przedstawia powstanie i rozwój Kliniki Traumatologii, Ortopedii i Chirurgii Ręki (początkowo nazywanej Kliniką Chirurgii Ręki) Uniwersytetu Medycznego w Poznaniu. Został napisany z okazji stulecia Wydziału Lekarskiego Uniwersytetu Poznańskiego, uczelni założonej w 1919 r., z której w 1950 r. wyodrębniona została Akademia Medyczna (od 2007 r. Uniwersytet Medyczny) w Poznaniu. Artykuł dostarcza gruntownej wiedzy o rozwoju Kliniki i ortopedach z nią związanych, zwłaszcza o prof. Hieronimie Strzyżewskim (1926-1971).
- 1 December 2019
- Published by Poznan University of Medical Sciences in Acta Medicorum Polonorum
- Vol. 9 (1-2) , 137-158
Poznan Clinic of Hand Surgery in the centenary of the Faculty of Medicine of the Poznan University
Artykuł przedstawia powstanie i rozwój Kliniki Traumatologii, Ortopedii i Chirurgii Ręki (początkowo nazywanej Kliniką Chirurgii Ręki) Uniwersytetu Medycznego w Poznaniu. Został napisany z okazji stulecia Wydziału Lekarskiego Uniwersytetu Poznańskiego, uczelni założonej w 1919 r., z której w 1950 r. wyodrębniona została Akademia Medyczna (od 2007 r. Uniwersytet Medyczny) w Poznaniu. Artykuł dostarcza gruntownej wiedzy o rozwoju Kliniki i ortopedach z nią związanych, zwłaszcza o prof. Hieronimie Strzyżewskim (1926-1971).